N-乙酰半胱氨酸重塑原发性和复发性小鼠胶质母细胞瘤的肿瘤微环境
研究探讨抗氧化剂N-乙酰半胱氨酸(NAC)对原发性和复发性小鼠胶质母细胞瘤的作用。NAC每日100 mg/kg治疗可降低小鼠脑肿瘤ROS水平、增加M1样TAMs和CD8+ T细胞浸润、使血管正常化,并抑制肿瘤生长和复发。NAC是重塑脑肿瘤微环境的有前景的辅助药物。
要点
- 人胶质母细胞瘤存在显著氧化应激。
- NAC治疗降低小鼠脑肿瘤ROS、增加M1样TAMs和CD8+ T细胞浸润、使血管正常化。
- NAC抑制小鼠脑肿瘤模型肿瘤生长并抑制复发。
核心结论
- NAC是重塑脑肿瘤微环境的有前景的辅助药物。
研究设计与样本
- 测量人胶质母细胞瘤中ROS/GSH水平。
- 在原发性小鼠脑肿瘤模型(GL261-Luc、CT2A-Luc)和复发性小鼠胶质母细胞瘤模型(GL261-iCasp9-Luc)中进行NAC试验。
- 脑肿瘤接种后,小鼠接受每日100 mg/kg NAC治疗,通过IVIS成像监测肿瘤体积。
主要发现
- 人胶质母细胞瘤遭受显著氧化应激。
- NAC治疗的小鼠脑肿瘤表现出较低的ROS水平、更多的M1样肿瘤相关巨噬细胞/小胶质细胞(TAMs)、更多的CD8+ T细胞浸润和正常化的血管特征。
- NAC抑制小鼠脑肿瘤模型中的肿瘤生长并抑制复发。
关键数值与推荐
- NAC剂量为每日100 mg/kg。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Glioblastoma (GBM) exhibits a high ROS character, giving rise to an immunosuppressive microenvironment and tumor vascular abnormality. This study investigated the potential effect of N-acetylcysteine (NAC), an antioxidant, on primary and recurrent mouse brain tumors. METHODS: We measured reactive oxygen species (ROS)/ glutathione (GSH) levels in human GBM. Additionally, we conducted NAC trials on primary mouse brain tumor models (GL261-Luc, CT2A-Luc) and a recurrent mouse GBM model (GL261-iCasp9-Luc). After brain tumor inoculation, mice received a daily 100 mg/kg NAC treatment, and the tumor volume was monitored via IVIS imaging. The efficacy of NAC was evaluated through survival time, tumor volume, ROS/GSH levels, M1/M2 macrophages, immune cells infiltration, and tumor vascularization. RESULTS: Human GBM suffered from significant oxidative stress. With NAC treatment, mouse brain tumors exhibited a lower ROS level, more M1-like tumor-associated macrophages/microglia (TAMs), more CD8 + T cell infiltration, and a normalized vascular character. NAC inhibited tumor growth and suppressed recurrence in mouse brain tumor models. CONCLUSION: NAC is a promising adjunctive drug to remodel the brain tumors microenvironment.
引用
- Zhu X, Yuan F, Sun Q, et al. N-acetylcysteine remodels the tumor microenvironment of primary and recurrent mouse glioblastoma. J Neurooncol. 2025. PMID: 39954037. doi:10.1007/s11060-025-04971-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。